The Indianapolis-based pharmaceutical company reported that 81% of participants achieved a clinical response to the drug at the 12-week induction mark. Among those initial responders, half reached full clinical remission by the end of the year-long study. These results provide a robust foundation for the company’s upcoming regulatory submissions.
In section Market Quotes
Eli Lilly’s Omvoh Shows Efficacy in Pediatric Ulcerative Colitis Trial
Eight in ten children with moderately to severely active ulcerative colitis responded to treatment with Eli Lilly’s Omvoh during a late-stage clinical trial. The study, involving patients aged 6 to 17, reached its primary endpoint by demonstrating significant clinical and endoscopic improvement over a 52-week observation period.
Eli Lilly intends to use this data to seek a label expansion for Omvoh, which is already authorized for adult patients suffering from the same inflammatory bowel disease. By targeting this younger demographic, the firm aims to address a critical gap in pediatric treatment options for chronic, debilitating digestive conditions.
Comments (0)
No comments yet. Be the first!